

**acceptable daily intake (ADI)** Amount of exposure determined to be “safe”; usually derived from the lowest No-Effect Level in an experimental study, divided by a safety factor such as 100. Also known as the Reference Dose (RfD).

**acetylation** The addition of an acetyl group from acetyl coenzyme A to a xenobiotic or xenobiotic metabolite by the enzyme *N*-acetyltransferase. Polymorphisms in this enzyme can be important in the expression of toxicity in humans.

**acetylator phenotype** Variation in the expression of *N*-acetyltransferase isoforms in humans gives rise to two subpopulations—fast and slow acetylators. Slow acetylators are more susceptible to the toxic effects of toxicants that are detoxified by acetylation.

**acid deposition** Wet and dry air pollutants that lower the pH of deposition and subsequently the pH of the environment. Acid rain with a pH of 4 or lower refers to the wet components. Normal rain has a pH of about 5.6. Sulfuric acid from sulfur and nitric acid from nitrogen oxides are the major contributors. In lakes in which the buffering capacity is low, the pH becomes acidic enough to cause fish kills, and the lakes cannot support fish populations. A contributing factor is the fact that acidic conditions concurrently release toxic metals, such as aluminum, into the water.

**activation (bioactivation)** In toxicology, this term is used to describe metabolic reactions of a xenobiotic in which the product is more toxic than is the substrate. Such reactions are most commonly monooxygenations, the products of which are electrophiles that, if not detoxified by phase II (conjugation) reactions, may react with nucleophilic groups on cellular macromolecules such as proteins and DNA.

**active oxygen** Used to describe various short-lived highly reactive intermediates in the reduction of oxygen. Active oxygen species such as superoxide anion and hydroxyl radical are known or believed to be involved in several toxic actions. Superoxide anion is detoxified by superoxide dismutase.

**acute toxicity tests** The most common tests for acute toxicity are the LC50 and LD50 tests, which are designed to measure mortality in response to an acute toxic insult. Other tests for acute toxicity include dermal irritation tests, dermal sensitization tests, eye irritation tests, photoallergy tests, and phototoxicity tests. *See also* eye irritation tests; LC50; and LD50.

**acute toxicity** Refers to adverse effects on, or mortality of, organisms following soon after a brief exposure to a chemical agent. Either a single exposure or multiple exposures within a short time period may be involved, and an acute effect is generally regarded as an effect that occurs within the first few days after exposure, usually less than two weeks.

**adaptation to toxicants** Refers to the ability of an organism to show insensitivity or decreased sensitivity to a chemical that normally causes deleterious effects. The terms resistance and tolerance are closely related and have been used in several different ways. However, a consensus is emerging to use the term *resistance* to mean that situation in which a change in the genetic constitution of a population in response to the stressor chemical enables a greater number of individuals to resist the toxic action than were able to resist it in the previous unexposed population. Thus an essential feature of resistance is selection and then inheritance by subsequent generations. In microorganisms, this frequently involves mutations and induction of enzymes by the toxicant; in higher organisms, it usually involves selection for genes already present in the population at low frequency. The term *tolerance* is then reserved for situations in which individual organisms acquire the ability to resist the effect of a toxicant, usually as a result of prior exposure.

**Ah locus** A gene(s) controlling the trait of responsiveness for induction of enzymes by aromatic hydrocarbons. In addition to aromatic hydrocarbons such as the polycyclics, the chlorinated dibenzo-*p*-dioxins, dibenzofurans, and biphenyls, as well as the brominated biphenyls, are involved. This trait, originally defined by studies of induction of hepatic aryl hydrocarbon hydroxylase activity following 3-methylcholanthrene treatment, is inherited by simple autosomal dominance in crosses and backcrosses between C57BL/6 (Ah-responsive) and DBA/2 (Ah-nonresponsive) mice.

**Ah receptor (AHR)** A protein coded for by a gene of the Ah locus. The initial location of the Ah receptor is believed to be in the cytosol and, after binding to a ligand such as TCDD, is transported to the nucleus. Binding of aromatic hydrocarbons to the Ah receptor of mice is a prerequisite for the induction of many xenobiotic metabolizing enzymes, as well as for two responses to TCDD; epidermal hyperplasia and thymic atrophy. Ah-responsive mice have a high-affinity receptor, whereas the Ah-nonresponsive mice have a low-affinity receptor.

**air pollution** In general, the principal air pollutants are carbon monoxide, oxides of nitrogen, oxides of sulfur, hydrocarbons, and particulates. The principal sources are transportation, industrial processes, electric power generation, and the heating of buildings. Hydrocarbons such as benzo(*a*)pyrene are produced by incomplete combustion and are associated primarily with the automobile. They are usually not present at levels high enough to cause direct toxic effects but are important in the formation of photochemical air pollution, formed as a result of interactions between oxides of nitrogen and hydrocarbons in the presence of ultraviolet light, giving rise to lung irritants such as peroxyacetyl nitrate, acrolein, and formaldehyde. Particulates are a heterogeneous group of particles, often seen as smoke, that are important as carriers of absorbed hydrocarbons and as irritants to the respiratory system.

**alkylating agents** These are chemicals that can add alkyl groups to DNA, a reaction that can result either in mispairing of bases or in chromosome breaks. The mechanism of the reaction involves the formation of a reactive carbonium ion that combines with electron-rich bases in DNA. Thus alkylating agents such as dimethylnitrosamine are frequently carcinogens and/or mutagens.

**Ames test** An *in vitro* test for mutagenicity utilizing mutant strains of the bacterium *Salmonella typhimurium* that is used as a preliminary screen of chemicals for assessing potential carcinogenicity. Several strains are available that cannot grow in the absence of histidine because of metabolic defects in histidine biosynthesis. Mutagens and presumed carcinogens can cause mutations that enable the strains to regain

their ability to grow in a histidine deficient medium. The test can be formed in the presence of the S-9 fraction from rat liver to allow the metabolic activation of promutagens. There is a high correlation between bacterial mutagenicity and carcinogenicity of chemicals.

**antagonism** In toxicology, antagonism is usually defined as that situation in which the toxicity to two or more compounds administered together is less than that expected from consideration of their toxicities when administered alone. Although this definition includes lowered toxicity resulting from induction of detoxifying enzymes, antagonism is frequently considered separately because of the time that must elapse between treatment with the inducer and subsequent treatment with the toxicant. Antagonism not involving induction is often at a marginal level of detection and is consequently difficult to explain. Such antagonism may involve competition for receptor sites or nonenzymatic combination of one toxicant with another to reduce the toxic effect. Physiological antagonism, in which two agonists act on the same physiological system but produce opposite effects, may also occur.

**antibody** A large protein first expressed on the surface of the B cells of the immune system, followed by a series of events resulting in a clone of plasma cells that secrete the antibody into body fluids. Antibodies bind to the substance (generally a protein) that stimulated their production but may cross-react with related proteins. The natural function is to bind foreign substances such as microbes or microbial products, but because of their specificity, antibodies are used extensively in research and in diagnostic and therapeutic procedures.

**antidote** A compound administered in order to reverse the harmful effect(s) of a toxicant. They may be toxic mechanism specific, as in the case of 2-pyridine aldoxime (2-PAM) and organophosphate poisoning, or nonspecific, as in the case of syrup of ipecac, used to induce vomiting and, thereby, elimination of toxicants from the stomach.

**behavioral toxicity** Behavior may be defined as an organism's motor or glandular response to changes in its internal or external environment. Such changes may be simple or highly complex, innate or learned, but in any event represent one of the final integrated expressions of nervous system function. Behavioral toxicity is adverse or potentially adverse effects on such expression brought about by exogenous chemicals.

**binding, covalent** *See* covalent binding.

**bioaccumulation** The accumulation of a chemical either from the medium (usually water) directly or from consumption of food containing the chemical. Biomagnification is often used as a synonym for bioaccumulation, but it is more correctly used to describe an increase in concentration of a chemical as it passes from organisms at one trophic level to organisms at higher trophic levels.

**bioactivation** *See* activation.

**bioassay** This term is used in two distinct ways. The first and most appropriate is the use of a living organism to measure the amount of a toxicant present in a sample or the toxicity of a sample. This is done by comparing the toxic effect of the sample with that of a graded series of concentrations of a known standard. The second and less appropriate meaning is the use of animals to investigate the toxic effects of chemicals as in chronic toxicity tests.

**burden of proof** Responsibility for determining whether a substance is safe or hazardous; a range of approaches can be seen when comparing laws. For example, for

OSHA, regulators show a substance is hazardous before exposure is restricted, with the government conducting the tests; for FDA, manufacturers must show lack of hazard before marketing.

**biomagnification** *See* bioaccumulation.

**carcinogen** Any chemical or process involving chemicals that induces neoplasms that are not usually observed, the earlier induction of neoplasms than are commonly observed, and/or the induction of more neoplasms than are usually found.

**carcinogen, epigenetic** Cancer-causing agents that exert their carcinogenic effect by mechanisms other than genetic, such as by immunosuppression, hormonal imbalance, or cytotoxicity. They may act as cocarcinogens or promoters. Epigenetic carcinogenesis is not as well understood a phenomenon as is genotoxic carcinogenesis.

**carcinogen, genotoxic** Cancer-causing agents that exert their carcinogenic effect by a series of events that is initiated by an interaction with DNA, either directly or through an electrophilic metabolite.

**carcinogen, proximate** *See* carcinogen, ultimate.

**carcinogen, ultimate** Many, if not most, chemical carcinogens are not intrinsically carcinogenic but require metabolic activation to express their carcinogenic potential. The term *procarcinogen* describes the initial reactive compound, the term *proximate* carcinogen describes its more active products, and the term *ultimate* carcinogen describes the product that is actually responsible for carcinogenesis by its interaction with DNA.

**carcinogenesis** This is the process encompassing the conversion of normal cells to neoplastic cells and the further development of these neoplastic cells into a tumor. This process results from the action of specific chemicals, certain viruses, or radiation. Chemical carcinogens have been classified into those that are genotoxic and those that are epigenetic (i.e., not genotoxic).

**chronic toxicity** This term is used to describe adverse effects manifested after a long time period of uptake of small quantities of the toxicant in question. The dose is small enough that no acute effects are manifested, and the time period is frequently a significant part of the expected normal lifetime of the organism. The most serious manifestation of chronic toxicity is carcinogenesis, but other types of chronic toxicity are also known (e.g., reproductive effects, behavioral effects).

**chronic toxicity tests** Chronic tests are those conducted over a significant part of the lifespan of the test species or, in some cases, more than one generation. The most important tests are carcinogenicity tests, and the most common test species are rats and mice.

**cocarcinogenesis** Cocarcinogenesis is the enhancement of the conversion of normal cells to neoplastic cells. This process is manifested by enhancement of carcinogenesis when the agent is administered either before or together with a carcinogen. Cocarcinogenesis should be distinguished from promotion as, in the latter case, the promoter must be administered after the initiating carcinogen.

**comparative toxicology** The study of the variation in the expression of the toxicity of exogenous chemicals toward organisms of different taxonomic groups or of different genetic strains.

**compartment** In pharmaco(toxico)kinetics a compartment is a hypothetical volume of an animal system wherein a chemical acts homogeneously in transport and transformation. These compartments do not correspond to physiological or anatomic

areas but are abstract mathematical entities useful for predicting drug concentrations. Transport into, out of, or between compartments is described by rate constants, which are used in models of the intact animal.

**conjugation reactions** *See* phase II reactions.

**covalent binding** This involves the covalent bond or “shared electron pair” bond. Each covalent bond consists of a pair of electrons shared between two atoms and occupying two stable orbitals, one of each atom. Although this is distinguished from the ionic bond or ionic valence, chemical bonds may in fact show both covalent and ionic character. In toxicology the term covalent binding is used less precisely to refer to the binding of toxicants or their reactive metabolites to endogenous molecules (usually macromolecules) to produce stable adducts resistant to rigorous extraction procedures. A covalent bond between ligand and macromolecule is generally assumed. Many forms of chronic toxicity involve covalent binding of the toxicant to DNA or protein molecules within the cell.

**cross resistance, cross tolerance** These terms describe the situation where either resistance or tolerance to a particular toxicant (as defined under adaptation to toxicants) is induced by exposure to a different toxicant. This is commonly seen in resistance of insects to insecticides in which selection with one insecticide brings about a broad spectrum of resistance to insecticides of the same or different chemical classes. Such cross resistance is usually caused by the inheritance of a high level of nonspecific xenobiotic-metabolizing enzymes.

**cytotoxicity** Cellular injury or death brought about by chemicals external to the cell. Such chemicals may be soluble mediators produced by the immune system, or they may be chemicals (toxicants) to which the organism has been exposed.

**Delaney Amendment** *See* Food, Drug, and Cosmetics Act.

**detoxication** A metabolic reaction or sequence of reactions that reduces the potential for adverse effect of a xenobiotic. Such sequences normally involve an increase in water solubility that facilitates excretion and/or the reaction of a reactive product with an endogenous substrate (conjugation), thereby not only increasing water solubility but also reducing the possibility of interaction with cellular macromolecules. Not to be confused with detoxification. *See also* detoxification.

**detoxification** Treatment by which toxicants are removed from intoxicated patients or a course of treatment during which dependence on alcohol or other drugs of abuse is reduced or eliminated. Not to be confused with detoxication. *See also* detoxication.

**distribution** The movement of a toxicant from the portal of entry to the tissue and also the different concentrations reached in different locations. The toxicant’s movement involves the study of transport mechanisms primarily in the blood, and both movement and concentration are subject to mathematical analysis in toxicokinetic studies.

**dosage** The amount of a toxicant drug or other chemical administered or taken expressed as some function of the organism, (e.g., mg/kg body weight/day).

**dose** The total amount of a toxicant, drug, or other chemical administered to or taken in by the organism.

**dose-response relationship** In toxicology the quantitative relationship between the amount of a toxicant administered or taken and the incidence or extent of the adverse effect.

**dose-response assessment** A step in the risk assessment process to characterize the relationship between the dose of a chemical administered to a population of test

animals and the incidence of a given adverse effect. It involves mathematical modeling techniques to extrapolate from the high-dose effects observed in test animals to estimate the effects expected from exposure to the typically low doses that may be encountered by humans.

**Draize test** *See* eye irritation test.

**drugs of abuse** Although all drugs may have deleterious effects on humans, drugs of abuse either have no medicinal function or are taken at higher than therapeutic doses. Some drugs of abuse may affect only higher nervous functions (i.e., mood, reaction time, coordination), but many produce physical dependence and have serious physical effects, with fatal overdose being a common occurrence. The drugs of abuse include central nervous system (CNS) depressants such as ethanol, methaqualone (Quaalude), and secobarbital; CNS stimulants such as cocaine, methamphetamine (speed), caffeine, and nicotine; opioids such as heroin and morphine; hallucinogens such as lysergic acid diethylamide (LSD), phencyclidine (PCP), and tetrahydrocannabinol (THC), the most important active principle of marijuana.

**drugs, therapeutic** All therapeutic drugs can be toxic at some dose. The danger to the patient is dependent on the nature of the toxic response, the dose necessary to produce the toxic response, and the relationship between the therapeutic and the toxic dose. Drug toxicity is affected by all of those factors that affect the toxicity of xenobiotics, including (genetic) variation, diet, age, and the presence of other exogenous chemicals. The risk of toxic side effects from a particular drug must be weighed against the expected benefits; the use of a quite dangerous drug with only a narrow tolerance between the therapeutic and toxic doses might well be justified if it is the sole treatment for an otherwise fatal disease. For example, cytotoxic agents used in the treatment of cancer are known carcinogens.

**ecotoxicology** *See* environmental toxicology.

**electron transport system (ETS)** This term is often restricted to the mitochondrial system, although it applies equally well to other systems, including that of microsomes and chloroplasts. The mitochondrial ETS (also termed respiratory chain or cytochrome chain) consists of a series of cytochromes and other electron carriers arranged in the inner mitochondrial membrane. These components transfer the electrons from NADH or FADH<sub>2</sub> generated in metabolic oxidations, to oxygen, the final electron acceptor, through a series of alternate oxidations and reductions. The energy that these electrons lose during these transfers is used to pump H<sup>+</sup> from the matrix into the intermembrane space, creating an electrochemical proton gradient that drives oxidative phosphorylation. The energy is conserved as adenosine triphosphate (ATP).

**electron transport system (ETS) inhibitors** The three major respiratory enzyme complexes of the mitochondrial electron transport system can all be blocked by inhibitors. For example, rotenone inhibits the NADH dehydrogenase complex, antimycin A inhibits the b-c complex, and cyanide and carbon monoxide inhibits the cytochrome oxidase complex. Although oxidative phosphorylation inhibitors prevent phosphorylation while allowing electron transfers to proceed, ETS inhibitors prevent both electron transport and ATP production.

**electrophilic** Electrophiles are chemicals that are attracted to and react with electron-rich centers in other molecules in reactions known as electrophilic reactions. Many activation reactions produce electrophilic intermediates such as epoxides, which exert

their toxic action by forming covalent bonds with nucleophilic centers in cellular macromolecules such as DNA or proteins.

**endoplasmic reticulum** The endoplasmic reticulum (ER) is an extensive branching and anastomosing double membrane distributed in the cytoplasm of eukaryotic cells. The ER is of two types: rough ER (RER) contains attached ribosomes on the cytosolic surface and smooth ER (SER), devoid of ribosomes are involved in protein biosynthesis; RER is abundant in cells specialized for protein synthesis. Many xenobiotic-metabolizing enzymes are integral components of both SER and RER, such as the cytochrome P450-dependent monooxygenase system and the flavin-containing monooxygenase, although the specific content is usually higher in SER. When tissue or cells are disrupted by homogenization, the ER is fragmented into many smaller (ca. 100 nm in diameter) closed vesicles called microsomes, which can be isolated by differential centrifugation.

**enterohepatic circulation** This term describes the excretion of a compound into the bile and its subsequent reabsorption from the small intestine and transport back to the liver, where it is available again for biliary excretion. The most important mechanism is conjugation in the liver, followed by excretion into the bile. In the small intestine the conjugation product is hydrolyzed, either nonenzymatically or by the microflora, and the compound is reabsorbed to become a substrate for conjugation and reexcretion into the bile.

**environmental toxicology** This is concerned with the movement of toxicants and their metabolites in the environment and in food chains and the effect of such toxicants on populations of organisms.

**epigenetic carcinogen** *See* carcinogen, epigenetic.

**exposure assessment** A component of risk assessment. The number of individuals likely to be exposed to a chemical in the environment or in the workplace is assessed, and the intensity, frequency, and duration of human exposure are estimated.

**eye irritation test (Draize test)** Eye irritation tests measure irritancy of compounds applied topically to the eye. These tests are variations of the Draize test, and the experimental animal used is the albino rabbit. The test consists of adding the material to be tested directly into the conjunctival sac of one eye of each of several albino rabbits, the other eye serving as the control. This test is probably the most controversial of all toxicity tests, being criticized primarily on the ground that it is inhumane. Moreover, because both concentrations and volumes used are high and show high variability, it has been suggested that these tests cannot be extrapolated to humans. However, because visual impairment is a critical toxic end point, tests for ocular toxicity are essential. Attempts to solve the dilemma have taken two forms: to find substitute *in vitro* tests and to modify the Draize test so that it becomes not only more humane but also more predictive for humans.

**Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA)** This law is the basic US law under which pesticides and other agricultural chemicals distributed in interstate commerce are registered and regulated. First enacted in 1947, FIFRA placed the regulation of agrochemicals under the control of the US Department of Agriculture. In 1970 this responsibility was transferred to the newly created Environmental Protection Agency (EPA). Subsequently FIFRA has been revised extensively by the Federal Environmental Pesticide Control Act (FEPCA) of 1972 and by the FIFRA amendments of 1975, 1978, and 1980. Under FIFRA all new pesticide products used in the United States must be registered with the EPA. This requires the registrant

to submit information on the composition, intended use, and efficacy of the product, along with a comprehensive database establishing that the material can be used without causing unreasonable adverse effects on humans or on the environment. The Food Quality Protection Act of 1996 is an amendment to FIFRA.

**fetal alcohol syndrome (FAS)** FAS refers to a pattern of defects in children born to alcoholic mothers. Three criteria for FAS are prenatal or postnatal growth retardation; characteristic facial anomalies such as microcephaly, small eye opening, and thinned upper lip; and central nervous system dysfunction, such as mental retardation and developmental delays.

**food additives** Chemicals may be added to food as preservatives (either antibacterial or antifungal compounds or antioxidants) to change the physical characteristics, for processing, or to change the taste or odor. Although most food additives are safe and without chronic toxicity, many were introduced when toxicity testing was relatively unsophisticated and some have been shown subsequently to be toxic. The most important inorganic additives are nitrate and nitrite. Well-known examples of food additives include the antioxidant butylatedhydroxyanisole (BHA), fungistatic agents such as methyl *p*-benzoic acid, the emulsifier propylene glycol, sweeteners such as saccharin and aspartame, and dyes such as tartrazine and Sunset Yellow.

**food contaminants (food pollutants)** Food contaminants, as opposed to food additives, are those compounds included inadvertently in foods that are raw, cooked, or processed. They include bacterial toxins such as the exotoxin of *Clostridium botulinum*, mycotoxins such as aflatoxins from *Aspergillus flavus*, plant alkaloids, animal toxins, pesticide residues, residues of animal food additives such as diethylstilbestrol (DES) and antibiotics, and a variety of industrial chemicals such as polychlorinated biphenyls (PCBs) and polybrominated biphenyls (PBBs).

**Food, Drug, and Cosmetics Act** The Federal Food, Drug, and Cosmetic Act is administered by the Food and Drug Administration (FDA). It establishes limits for food additives, sets criteria for drug safety for both human and animal use, and requires proof of both safety and efficacy. This act contains the Delaney Amendment, which states that food additives that cause cancer in humans or animals at any level shall not be considered safe and are, therefore, prohibited. The Delaney Amendment has been modified to permit more flexible use of mechanistic and cost-benefit data. This law also empowers the FDA to establish and modify the Generally Recognized as Safe (GRAS) list and to establish Good Laboratory Practice (GLP) rules. As a result of the Food Quality Protection (1996), the Delaney Amendment no longer applies to chemicals regulated under FIFRA.

**forensic toxicology** Forensic toxicology is concerned with the medicolegal aspects of the adverse effects of chemicals on humans and animals. Although primarily devoted to the identification of the cause and circumstances of death and the legal issues arising there from, forensic toxicologists also deal with sublethal poisoning cases.

**free radicals** Molecules that have unpaired electrons. Free radicals may be produced metabolically from xenobiotics and, because they are extremely reactive, may be involved in interactions with cellular macromolecules, giving rise to adverse effects. Examples include the trichloromethyl radical produced from carbon tetrachloride or the carbene radical produced by oxidation of the acetal carbon of methylenedioxyphenyl synergists.

**genotoxic carcinogen** *See* carcinogen, genotoxic.

**genotoxicity** Genotoxicity is an adverse effect on the genetic material (DNA) of living cells that, on the replication of the cells, is expressed as a mutagenic or a carcinogenic event. Genotoxicity results from a reaction with DNA that can be measured either biochemically or in short-term tests with end points that reflect DNA damage.

**Good Laboratory Practice (GLS)** In the United States this is a code of laboratory procedures laid down under federal law and to be followed by laboratories undertaking toxicity tests whose results will be used for regulatory or legal purposes.

**Generally Regarded as Safe (GRAS) list** *See* Food, Drug, and Cosmetics Act.

**hazard identification** Considered the first step in risk assessment, hazard identification involves the qualitative determination of whether exposure to a chemical causes an increased incidence of an adverse effect, such as cancer or birth defects, in a population of test animals and an evaluation of the relevance of this information to the potential for causing similar effects in humans.

**hepatotoxicity** Hepatotoxicants are those chemicals causing adverse effects on the liver. The liver may be particularly susceptible to chemical injury because of its anatomic relationship to the most important portal of entry, the gastrointestinal (GI) tract, and its high concentration of xenobiotic-metabolizing enzymes. Many of these enzymes, particularly cytochrome P450, metabolize xenobiotics to produce reactive intermediates that can react with endogenous macromolecules such as proteins and DNA to produce adverse effects.

**immunotoxicity** This term can be used in either of two ways. The first refers to toxic effects mediated by the immune system, such as dermal sensitivity reactions to compounds like 2,4-dinitrochlorobenzene. The second, and currently most acceptable definition, refers to toxic effects that impair the functioning of the immune system—for example, the ability of a toxicant to impair resistance to infection.

**in vitro tests** Literally these are tests conducted outside of the body of the organism. In toxicity testing they would include studies using isolated enzymes, subcellular organelles, or cultured cells. Although technically the term would not include tests involving intact eukaryotes (e.g., the Ames test), it frequently is used by toxicologists to include all short-term tests for mutagenicity that are normally used as indicators of potential carcinogenicity.

**in vivo tests** Tests carried out on the intact organism, although the evaluation of the toxic end point almost always requires pathological or biochemical examination of the test organism's tissues. They may be acute, subchronic, or chronic. The best known are the lifetime carcinogenesis tests carried out on rodents.

**induction** The process of causing a quantitative increase in an enzyme as a result of de novo protein synthesis following exposure to an inducing agent. This can occur either by a decrease in the degradation rate or an increase in the synthesis rate or both. Increasing the synthesis rate is the most common mechanism for induction by xenobiotics. Coordinate (pleiotypic) induction is the induction of multiple enzymes by a single inducing agent. For example, phenobarbital can induce isozymes of both cytochrome P450 and glutathione *S*-transferase.

**industrial toxicology** A specific area of environmental toxicology dealing with the work environment; it includes risk assessment, establishment of permissible levels of exposure, and worker protection.

**inhibition** In its most general sense, inhibition means a restraining or a holding back. In biochemistry and biochemical toxicology, inhibition is a reduction in the rate of

an enzymatic reaction, and an inhibitor is any compound causing such a reduction. Inhibition of enzymes important in normal metabolism is a significant mechanism of toxic action of xenobiotics, whereas inhibition of xenobiotic-metabolizing enzymes can have important consequences in the ultimate toxicity of their substrates. Inhibition is sometimes used in toxicology in a more general and rather ill-defined way to refer to the reduction of an overall process of toxicity, as in the inhibition of carcinogenesis by a particular chemical.

**initiation** The initial step in the carcinogenic process involving the conversion of a normal cell to a neoplastic cell. Initiation is considered to be a rapid and essentially irreversible change involving the interaction of the ultimate carcinogen with DNA; this change primes the cell for subsequent neoplastic development via the promotion process.

**intoxication** In the general sense, this term refers primarily to inebriation with ethyl alcohol, secondarily to excitement or delirium caused by other means, including other chemicals. In the clinical sense it refers to poisoning or becoming poisoned. In toxicology it is sometimes used as a synonym for activation—that is, the production of a more toxic metabolite from a less toxic parent compound. This latter use of intoxication is ambiguous and should be abandoned in favor of the aforementioned general meanings, and activation or bioactivation used instead.

**isozymes (isoenzymes)** Isozymes are multiple forms of a given enzyme that occur within a single species or even a single cell and that catalyze the same general reaction but are coded for by different genes. Different isozymes may occur at different life stages and/or in different organs and tissues, or they may coexist within the same cell. The first well-characterized isozymes were those of lactic dehydrogenase. Several xenobiotic-metabolizing enzymes exist in multiple isozymes, including cytochrome P450 and glucuronosyltransferase.

**LC50 (median lethal concentration)** The concentration of a test chemical that, when a population of test organisms is exposed to it, is estimated to be fatal to 50% of the organisms under the stated conditions of the test. Normally used in lieu of the LD50 test in aquatic toxicology and inhalation toxicology.

**LD50 (median lethal dose)** The quantity of a chemical compound that, when applied directly to test organisms, is estimated to be fatal to 50% of those organisms under the stated conditions of the test. The LD50 value is the standard for comparison of acute toxicity between toxicants and between species. Because the results of LD50 determinations may vary widely, it is important that both biological and physical conditions be narrowly defined (e.g., strain, gender, and age of test organism; time and route of exposure; environmental conditions). The value may be determined graphically from a plot of log dose against mortality expressed in probability units (probits) or, more recently, by using one of several computer programs available.

**lethal synthesis** This term is used to describe the process by which a toxicant, similar in structure to an endogenous substrate, is incorporated into the same metabolic pathway as the endogenous substrate, ultimately being transformed into a toxic or lethal product. For example, fluoroacetate simulates acetate in intermediary metabolism, being transformed via the tricarboxylic acid cycle to fluorocitrate, which then inhibits aconitase, resulting in disruption of the TCA cycle and energy metabolism.

**lipophilic** The physical property of chemical compounds that causes them to be soluble in nonpolar solvents (e.g., chloroform and benzene) and, generally, relatively insoluble in polar solvents such as water. This property is important toxicologically

because lipophilic compounds tend to enter the body easily and to be excretable only when they have been rendered less lipophilic by metabolic action.

**maximum tolerated dose (MTD)** The MTD has been defined for testing purposes by the US environmental Protection Agency as the highest dose that causes no more than a 10% weight decrement, as compared to the appropriate control groups, and does not produce mortality, clinical signs of toxicity, or pathologic lesions (other than those that may be related to a neoplastic response) that would be predicted to shorten the animals' natural life span. It is an important concept in chronic toxicity testing; however, the relevance of results produced by such large doses has become a matter of controversy.

**mechanism of action** *See* mode of action.

**membranes** Membranes of tissues, cells, and cell organelles are all basically similar in structure. They appear to be bimolecular lipid leaflets with proteins embedded in the matrix and also arranged on the outer polar surfaces. This basic plan is present despite many variations, and it is important in toxicological studies of uptake of toxicants by passive diffusion and active transport.

**microsomes** Microsomes are small closed vesicles (ca.110 nm in diameter) that represent membrane fragments formed from the endoplasmic reticulum when cells are disrupted by homogenization. Microsomes are separated from other cell organelles by differential centrifugation. The cell homogenate contains rough microsomes that are studded with ribosomes and are derived from rough endoplasmic reticulum, and smooth microsomes that are devoid of ribosomes and are derived from smooth endoplasmic reticulum. Microsomes are important preparations for studying the many processes carried out by the endoplasmic reticulum, such as protein biosynthesis and xenobiotic metabolism.

**mode of action (mode of toxic action)** Terms used to describe the mechanism(s) that enables a toxicant to exert its toxic effect. The term(s) may be narrowly used to describe only those events at the site of action (perhaps better referred to as mechanism of action), or more broadly, to describe the sequence of events from uptake from the environment, through metabolism, distribution, and so on, up to and including events at the site of action.

**monooxygenase (mixed-function oxidase)** An enzyme for which the co-substrates are an organic compound and molecular oxygen. In reactions catalyzed by these enzymes, one atom of a molecule of oxygen is incorporated into the substrate, whereas the other atom is reduced to water. Monooxygenases of importance in toxicology include cytochrome P450 and the flavin-containing monooxygenase, both of which initiate the metabolism of lipophilic xenobiotics by the introduction of a reactive polar group into the molecule. Such reactions may represent detoxication or may generate reactive intermediates of importance in toxic action. The term mixed-function oxidase is now considered obsolete and should not be used. The term multifunction oxidase was never widely adopted and also should not be used.

**mutagenicity** Mutations are heritable changes produced in the genetic information stored in the DNA of living cells. Chemicals capable of causing such changes are known as mutagens, and the process is known as mutagenesis.

**mycotoxins** Toxins produced by fungi. Many, such as aflatoxins, are particularly important in toxicology.

**nephrotoxicity** A pathologic state that can be induced by chemicals (nephrotoxicants) and in which the normal homeostatic functioning of the kidney is impaired. It is often associated with necrosis of the proximal tubule.

**neurotoxicity** This is a general term referring to all toxic effects on the nervous system, including toxic effects measured as behavioral abnormalities. Because the nervous system is complex, both structurally and functionally, and has considerable functional reserve, the study of neurotoxicity is a many-faceted branch of toxicology. It involves electrophysiology, receptor function, pathology, behavior, and other aspects.

**No Observed Effect Level (NOEL)** This is the highest dose level of a chemical that, in a given toxicity test, causes no observable effect in the test animals. The NOEL for a given chemical varies with the route and duration of exposure and the nature of the adverse effect (i.e., the indicator of toxicity). The NOEL for the most sensitive test species and the most sensitive indicator of toxicity is usually employed for regulatory purposes. Effects considered are usually adverse effects, and this value may be called the No Observed Adverse Effects Level (NOAEL).

**Occupational Safety and Health Administration (OSHA)** In the United States, OSHA is the government agency concerned with health and safety in the workplace. Through the administration of the Occupational Safety and Health Act, OSHA sets the standards for worker exposure to specific chemicals, for air concentration values, and for monitoring procedures. OSHA is also concerned with research (through the National Institute for Occupational Safety and Health, NIOSH), information, education, and training in occupational safety and health.

**oncogenes** Oncogenes are genes that, when activated in cells, can transform the cells from normal to neoplastic. Sometimes oncogenes are carried into normal cells by infecting viruses, particularly, RNA viruses or retroviruses. In some cases, however, the oncogene is already present in the normal human cell, and it needs only a mutation or other activating event to change it from a harmless and possible essential gene, called *proto-oncogene*, into a cancer-producing gene. More than 30 oncogenes have been identified in humans.

**oxidative phosphorylation** The conservation of chemical energy extracted from fuel oxidations by the phosphorylation of adenosine diphosphate (ADP) by inorganic phosphate to form adenosine triphosphate (ATP) is accomplished in several ways. The majority of ATP is formed by respiratory chain-linked oxidative phosphorylation associated with the electron transport system in the mitochondrial inner membrane. The oxidations are tightly coupled to phosphorylations through a chemiosmotic mechanism in which  $H^+$  are pumped across the inner mitochondrial membrane. Uncouplers of oxidative phosphorylation serve as  $H^+$  ionophores to dissipate the  $H^+$  gradient, and thus uncouple the phosphorylations from the oxidations.

**oxidative stress** Damage to cells and cellular constituents and processes by reactive oxygen species generated in situ. Oxidative stress may be involved in such toxic interactions as DNA damage, lipid peroxidation, and pulmonary and cardiac toxicity. Because of the transitory nature of most reactive oxygen species, although oxidative stress is often invoked as a mechanism of toxicity, rigorous proof may be lacking.

**partition coefficient** This is a measure of the relative lipid solubility of a chemical and is determined by measuring the partitioning of the compound between an organic phase and an aqueous phase (e.g., octanol and water). The partition coefficient is important in studies of the uptake of toxicants because compounds with high

coefficients (lipophilic compounds) are usually taken up more readily by organisms and tissues.

**pharmacokinetics** The study of the quantitative relationship between absorption, distribution, and excretion of chemicals and their metabolites. It involves derivation of rate constants for each of these processes and their integration into mathematical models that can predict the distribution of the chemical throughout the body compartments at any point in time after administration. Pharmacokinetics have been carried out most extensively in the case of clinical drugs. When applied specifically to toxicants, the term *toxicokinetics* is often used.

**phase I reactions** These reactions introduce a reactive polar group into lipophilic xenobiotics. In most cases this group becomes the site for conjugation during phase II reactions. Such reactions include microsomal monooxygenations, cytosolic and mitochondrial oxidations, cooxidations in the prostaglandin synthetase reaction, reductions, hydrolyses, and epoxide hydrolases. The products of phase I reactions may be potent electrophiles that can be conjugated and detoxified in phase II reactions or that may react with nucleophilic groups on cellular constituents, thereby causing toxicity.

**phase II reactions** Reactions involving the conjugation with endogenous substrates of phase I products and other xenobiotics that contain functional groups such as hydroxyl, amino, carboxyl, epoxide, or halogen. The endogenous metabolites include sugars, amino acids, glutathione, and sulfate. The conjugation products, with rare exceptions, are more polar, less toxic, and more readily excreted than are their parent compounds. There are two general types of conjugations: type I (e.g., glycoside and sulfate formation), in which an activated conjugating agent combines with substrate to yield the conjugated product, and type II (e.g., amino acid conjugation), in which the substrate is activated and then combines with an amino acid to yield a conjugated product.

**poison (toxicant)** A poison (toxicant) is any substance that causes a harmful effect when administered to a living organism. Due to a popular connotation that poisons are, by definition, fatal in their effects and that their administration is usually involved with attempted homicide or suicide, most toxicologists prefer the less prejudicial term toxicant. Poison is a quantitative concept. Almost any substance is harmful at some dose and, at the same time, is harmless at a very low dose. There is a range of possible effects, from subtle long-term chronic toxicity to immediate lethality.

**pollution** This is contamination of soil, water, food, or the atmosphere by the discharge or admixture of noxious materials. A pollutant is any chemical or substance contamination the environment and contributing to pollution.

**portals of entry** The sites at which xenobiotics enter the body. They include the skin, the gastrointestinal (GI) tract, and the respiratory system.

**potentiation** See synergism and potentiation.

**procarcinogen** See carcinogen, ultimate.

**promotion** The facilitation of the growth and development of neoplastic cells into a tumor. This process is manifested by enhancement of carcinogenesis when the agent is given after a carcinogen.

**pulmonary toxicity** This term refers to the effects of compounds that exert their toxic effects on the respiratory system, primarily the lungs.

**quantitative structure activity relationships (QSAR)** The relationship between the physical and/or chemical properties of chemicals and their ability to cause a particular

effect, enter into particular reactions, and so on. The goal of QSAR studies in toxicology is to develop procedures whereby the toxicity of a compound can be predicted from its chemical structure by analogy with the properties of other toxicants of known structure and toxic properties.

**reactive intermediates (reactive metabolites)** Chemical compounds, produced during the metabolism of xenobiotics, that are more chemically reactive than is the parent compound. Although they are susceptible to detoxication by conjugation reactions, these metabolites, as a consequence of their increased reactivity, have a greater potential for adverse effects than does the parent compound. A well-known example is the metabolism of benzo(a)pyrene to its carcinogenic dihydrodiol epoxide derivative as a result of metabolism by cytochrome P450 and epoxide hydrolase. Reactive intermediates involved in toxic effects include epoxides, quinones, free radicals, reactive oxygen species, and a small number of unstable conjugation products.

**reference dose (RfD)** See acceptable daily intake (ADI).

**resistance** See adaptation to toxicants.

**Resource Conservation and Recovery Act (RCRA)** Administered by the EPA, the RCRA is the most important act governing the disposal of hazardous wastes in the United States; it promulgates standards for identification of hazardous wastes, their transportation, and their disposal. Included in the last are siting and construction criteria for landfills and other disposal facilities as well as the regulation of owners and operators of such facilities.

**risk assessment (risk analysis)** The process by which the potential adverse health effects of human exposure to chemicals are characterized; it includes the development of both qualitative and quantitative expression of risk. The process of risk assessment may be divided into four major components: hazard identification, dose-response assessment (high-dose to low-dose extrapolation), exposure assessment, and risk characterization.

**risk, toxicologic** The probability that some adverse effect will result from a given exposure to a chemical is known as the risk. It is the estimated frequency of occurrence of an event in a population and may be expressed in absolute terms (e.g., 1 in 1 million) or in terms of relative risk (i.e., the ratio of the risk in question to that in an equivalent unexposed population).

**safety factor (uncertainty factor)** A number by which the no observed effect level (NOEL) is divided to derive the reference dose (RfD), the reference concentration (RfC) or minimum risk level (MRL) of a chemical from experimental data. The safety factor is intended to account for the uncertainties inherent in estimating the potential effects of a chemical on humans from results obtained with test species. The safety factor allows for possible difference insensitivity between the test species and humans, as well as for variations in the sensitivity within the human population. The size of safety factor (e.g., 100–1000) varies with confidence in the database and the nature of the adverse effects. Small safety factors indicate a high degree of confidence in the data, an extensive database, and/or the availability of human data. Large safety factors are indicative of an inadequate and uncertain database and/or the severity of the unexpected toxic effect.

**selectivity (selective toxicity)** A characteristic of the relationship between toxic chemicals and living organisms whereby a particular chemical may be highly toxic to one species but relatively innocuous to another. The search for and study of selective

toxicants is an important aspect of comparative toxicology because chemicals toxic to target species but innocuous to nontarget species are extremely valuable in agriculture and medicine. The mechanisms involved vary from differential penetration rates through different metabolic pathways to differences in receptor molecules at the site of toxic action.

**solvents** In toxicology this term usually refers to industrial solvents. These belong to many different chemical classes and a number of these are known to cause problems of toxicity to humans. They include aliphatic hydrocarbons (e.g., hexane), halogenated aliphatic hydrogens (e.g., methylene chloride), aliphatic alcohols (e.g., methanol), glycols and glycol ethers (e.g., propylene and propylene glycol), and aromatic hydrocarbons (e.g., toluene).

**subchronic toxicity** Toxicity due to chronic exposure to quantities of a toxicant that do not cause any evident acute toxicity for a time period that is extended but is not so long as to constitute a significant part of the lifespan or the species in question. In subchronic toxicity tests using mammals, a 30- to 90-day period is considered appropriate.

**synergism and potentiation** The terms synergism and potentiation have been variously used and defined but in any case involve a toxicity that is greater when two compounds are given simultaneously or sequentially than would be expected from a consideration of the toxicities of the compounds given alone. In an attempt to make the use of these terms uniform, it is suggested that, insofar as toxic effects are concerned, they be used as defined as follows: both involve toxicity greater than would be expected from the toxicities of the compounds administered separately, but in the case of synergism one compound has little or no intrinsic toxicity administered alone, whereas in the case of potentiation both compounds have appreciable toxicity when administered alone.

**teratogenesis** This term refers to the production of defects in the reproduction process resulting in either reduced productivity due to fetal or embryonic mortality or the birth of offspring with physical, mental, behavioral, or developmental defects. Compounds causing such defects are known as teratogens.

**therapy** Poisoning therapy may be nonspecific or specific. Nonspecific therapy is treatment for poisoning that is not related to the mode of action of the particular toxicant. It is designed to prevent further uptake of the toxicant and to maintain vital signs. Specific therapy, however, is therapy related to the mode of action of the toxicant and not simply to the maintenance of vital signs by treatment of symptoms. Specific therapy may be based on activation and detoxication reactions, on mode of action, or on elimination of the toxicant. In some cases more than one antidote, with different modes of action, is available for the same toxicant.

**threshold dose** This is the dose of a toxicant below which no adverse effect occurs. The existence of such a threshold is based on the fundamental tenet of toxicology that, for any chemical, there exists a range of doses over which the severity of the observed effect is directly related to the dose, the threshold level representing the lower limit of this dose range. Although practical thresholds are considered to exist for most adverse effects, for regulatory purposes it is assumed that there is no threshold dose for carcinogens.

**threshold limit value (TLV)** The upper permissive limit of airborne concentrations of substances represents conditions under which it is believed that nearly all workers may be exposed repeatedly, day after day, without adverse effect. Threshold

limits are based on the best available information from industrial experience, from experimental human and animal studies, and, when possible, from a combination of the three.

**threshold limit value—ceiling (TLV-C)** This is the concentration that should not be exceeded even momentarily. For some substances (e.g., irritant gases), only one TLV category, the TLV-C, may be relevant. For other substances, two or three TLV categories may need to be considered.

**threshold limit value—short-term exposure limit (TLV-STEL)** This is the maximal concentration to which workers can be exposed for a period up to 15 minutes continuously without suffering from (1) irritation, (2) chronic or irreversible tissue change, or (3) narcosis of sufficient degree to increase accident proneness.

**threshold limit value—time-weighted average (TLV-TWA)** This is the TWA concentration for a normal 8-hour workday or 40-hour workweek to which nearly all workers may be exposed repeatedly day after day, without adverse effect. Time-weighted averages allow certain permissible excursions above the limit, provided that they are compensated by equivalent excursions below the limit during the workday. In some instances the average concentration is calculated for a workweek rather than for a workday.

**tolerance** *See* adaptation to toxicants.

**Toxic Substances Control Act (TSCA)** Enacted in 1976, the TSCA provides the EPA with the authority to require testing and to regulate chemicals, both old and new, entering the environment. It was intended to supplement sections of the Clean Air Act, the Clean Water Act, and the Occupational Safety and Health Act that already provide for regulation of chemicals. Manufacturers are required to submit information to allow the EPA to identify and evaluate the potential hazards of a chemical prior to its introduction into commerce. The act also provides for the regulation of production, use, distribution and disposal of chemicals.

**toxicant** *See* poison.

**toxicokinetics** *See* pharmacokinetics.

**toxicology** Toxicology is defined as that branch of science that deals with poisons (toxicants) and their effects; a poison is defined as any substance that causes a harmful effect when administered, either by accident or design, to a living organism. There are difficulties in bringing a more precise definition to the meaning of poison and in the definition and measurement of toxic effect. The range of deleterious effects is wide and varies with species, gender, developmental stage, and so on, while the effects of toxicants are always dose dependent.

**toxin** This is a toxicant produced by a living organism. Toxin should never be used as a synonym for toxicant.

**transport** In toxicology this term refers to the mechanisms that bring about movement of toxicants and their metabolites from one site in the organism to another. *Transport* usually involves binding to either blood albumins or blood lipoproteins.

**ultimate carcinogen** *See* carcinogen, ultimate.

**venom** A venom is a toxin produced by an animal specifically for the poisoning of other species via a mechanism designed to deliver the toxin to its prey. Examples include the venom of bees and wasps, delivered by a sting, and the venom of snakes, delivered by fangs.

**water pollution** Water pollution is of concern in both industrialized and nonindustrialized nations. Chemical contamination is more common in industrialized nations, whereas microbial contamination is more important in nonindustrialized areas. Surface water contamination has been the primary cause for concern, but since the discovery of agricultural and industrial chemicals in groundwater, contamination of water from this source is also a problem. Water pollution may arise from runoff of agricultural chemicals, from sewage, or from specific industrial sources. Agricultural chemicals found in water include insecticides, herbicides, fungicides, and nematocides; fertilizers, although less of a toxic hazard, contribute to such environmental problems as eutrophication. Other chemicals of concern include low molecular-weight halogenated hydrocarbons such as chloroform, dichloroethane, and carbon tetrachloride; polychlorinated biphenyls (PCBs); chlorophenols; 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD); phthalate ester plasticizers; detergents; and a number of toxic inorganics.

**xenobiotic** A general term used to describe any chemical interacting with an organism that does not occur in the normal metabolic pathways of that organism. The use of this term in lieu of “foreign compound,” among others, has gained wide acceptance.



## INDEX

- A**
- Absorption, 77–110  
dermal, 91–94  
gastrointestinal, 89–91  
respiratory, 94–97
- Acceptable daily intake, 427, 525, 538
- Acetaminophen, 123, 140, 154, 158, 160, 265, 271, 272, 274
- Acetylaminofluorene, 121, 122, 125, 126, 157, 158, 175, 265, 268
- Acetylation, 146, 525
- Acetylator phenotype, 525
- Acetylcholine, 220, 221
- Acetylcholinesterase, 60, 155, 290, 291, 296
- N*-Acetylcysteine, 154
- Acylesterase, 220, 221
- N*-Acetyltransferase, 146, 525
- Acetylsalicylic acid, *see* Aspirin
- Acid deposition, 39, 525
- ACR—*see* Acute to chronic ratio
- Action potential, 281, 287
- Actinomycin A, 223
- Actinomycin D, 345
- Activation, 149, 150, 152, 243, 274, 525
- Active oxygen, 525
- Acutane, 256
- Acute to chronic ratio, 473
- Acute toxicity—*see* Toxicity
- Acylation, 145, 146
- Acyltransferase, 146
- Adaptation, to toxicants, 182, 526, 538
- S-Adenosyl methionine (SAM), 141
- ADI—*see* Acceptable daily intake
- Adjuvants, 339–341
- Administration of toxicants, 4
- Adrenals, 171, 300
- Adrenocorticotrophic hormone, metabolic effects, 171
- Advection, 483–485
- A-Esterase—*see* Esterase
- Aflatoxin, 121, 122–124, 152, 156, 237–238, 248, 265
- Aflatoxin dihydrodiol, 156
- Agonist, 306, 308, 309
- Agricultural chemicals, 7, 54–64
- Ah locus, 526
- Ah receptor—*see* Arylhydrocarbon receptor
- Air pollution, 33, 331, 338–341, 419, 526
- Airways, 317
- Albumin, 311
- Alcohol dehydrogenase, 112, 130, 155, 186
- Alcohols, 220
- Aldehyde dehydrogenase, 112, 130, 155
- Aldehyde reduction, 134
- Aldrin, 112, 124
- Algal toxins, 67
- Aliphatic epoxidation, 124
- Aliphatic hydroxylation, 112, 124
- Alkylating agents, 526
- Allergens  
food, 341  
respiratory, 338
- Allergic contact dermatitis, 337–338
- Allergic response, 321
- Allergy, 336–341
- Allyl alcohol, 265
- Allylisopropylacetamide, 185, 189
- Altitude, metabolic effects, 200
- Aluminum, 318
- Alveolar ducts, 317
- Alveoli, 317
- American Conference of Governmental Industrial Hygienists, 418
- Ames test, 249, 385, 526
- Amidase, 112, 135, 175
- Amine oxidase, 131
- Amines, 220
- Amino acid conjugation, 147
- 1-Aminobenzotriazole, 185
- 4-Aminobiphenyl, 121

- $\gamma$ -Aminobutyric acid, 222  
 2-Aminofluorene, 129  
 Aminoglycosides, 276  
 Amitriptyline, 265  
 Ammonia, 318  
 Amphetamine, 126  
 Analytical methods files, 25  
 Androgen receptor—see Receptors  
 Androgens, 119, 300  
 Aneuploidy, 245  
 Aniline hydroxylation, 174, 175  
 Animal husbandry, in toxicity testing,  
     365–366  
 Antagonism, 190, 527  
 Antagonist, 308, 309  
 Antibodies  
     definition, 527  
     inhibitory, 21  
     monoclonal, 19–20  
     polyclonal, 19–20  
 Antibody-forming cell assay, 331–332  
 Aniline hydroxylation, 174, 175  
 Antidote, 527  
 Antimony, 181  
 Antipyrine metabolism, 186  
 Apoptosis, 227, 241–242, 245, 248, 266  
 Arachidonic acid, 122, 132  
 Aromatic hydroxylation, 112, 123  
 Arsenic, 41, 44, 53, 318, 408  
 Artemisinin, 122  
 Arylesterases, 135  
 Arylhydrocarbon receptor (Ah receptor),  
     121, 192, 526  
 Arylhydroxamic acid, 147  
 Asbestos, 46, 47, 318  
 Asbestosis, 318  
 Aspirin, 4  
 Asthma, 338–339  
 Astrocyte, 281, 284, 290  
 ATP synthetase, 223  
 Atrazine, 464, 467, 474, 482  
 Auditory startle, 383  
 Autoimmune disease, 327, 336, 341  
 Autonomic, 280–291  
 Avermectin, 222  
 Avian testing, 394  
 Axon, 280, 281, 285–286, 287–288  
 Axonal transport, 285–286  
 5-Aza-2-deoxycytine, 345  
 Azaserine, 265  
 Azide, 223  
 Azo reduction, 112, 133, 180
- B**  
 Barbie box, 194  
 Behavioral toxicity—see Toxicity  
*Belladonna*, 4, 173  
 Benchmark dose, 430  
 Benzene, 46, 47, 123  
 Benzydine, 121, 146  
 Benzoic acid, 146  
 Benzoperylene, 464  
 Benzo(a)pyrene, 237, 243–245, 248,  
     322  
     activation, 158  
     metabolism, 159  
*N*-Benzylamidazole, 130  
 Beryllium, 265, 318  
 B-Esterase—see Esterase  
 Bile canaliculi, 208, 209, 263  
 Bile duct, 263, 207, 209  
 Bilirubin, 139  
 Binding, covalent—see Covalent binding  
 Bioaccumulation, 467, 468, 469, 470, 472,  
     527  
 Bioactivation—see Activation  
 Bioassay, 527  
 Bioavailability, 77  
 Biochemical methods, in toxicology,  
     13–22  
 Bioconcentration, 488—see also  
     Bioaccumulation  
 Biomagnification, 467—see also  
     Bioaccumulation  
 Biomethylation, of elements, 142  
 Bioremediation, 465  
 Biotransformation, 495  
 Blastocyst, 253  
 Blending, 447  
 Blood coagulation, 300  
 Blood urea nitrogen (BUN), 274  
 Bluegill, 394  
 B lymphocytes—see Lymphocytes, B  
 Bobwhite quail, 394  
 Bone density, 300  
 Botanical insecticides, 60–61  
 Botulinum toxin, 292  
 Bowman's capsule, 206  
 Bromobenzene, 265, 270  
 Bromobenzene metabolites, 271, 272, 274  
 Bronchi, 317  
 Bronchioles, 317  
 Bronchitis, 318  
 BUN—see Blood urea nitrogen  
 Bupropion, 122  
 Burden of proof, 527

- 1,3-Butadiene, 122  
2-Butanol, 140
- C**
- Cadmium, 41, 46, 51, 52, 275, 318  
Calcium homeostasis, 266  
Cancer  
  incidence and mortality, 228–231  
  lung, 318, 321, 322  
  nasal, 318  
  process, 225–227  
  susceptibility, 229–230  
Capillary electrophoresis, 454  
CAR—*see* Constitutive active receptor  
Carbamate(s), 20, 60, 221, 408, 471, 477  
Carbaryl, 123, 473  
Carbasone, 265  
Carbofuran, 464  
Carbohydrates, metabolic effects, 164  
Carbon monoxide, 36  
  spectrum, 114  
Carbon tetrachloride, 4, 123, 153, 156,  
  173, 189, 265, 269, 274  
Carbophenothion sulfoxide, 134  
Carboxylesterase, 135  
Carcinogen(s), 3, 121, 528  
  classification of human carcinogens,  
    233–237  
  direct-acting, 237  
  epigenetic, 239–240, 528  
  genotoxic, 237–238, 528  
  indirect-acting, 237  
  known human, 233–235  
  procarcinogen, 150  
  parent, 240  
  proximate, 150, 240, 528  
  ultimate, 150, 240, 528  
Carcinogenesis, 6, 225–250, 267, 528  
  rodent bioassay, 233–234  
  testing, 371–378  
Carson, Rachel, 9  
Catechol O-methyltransferase, 142  
Cell culture  
  cell lines, 15  
  induction, in cultured cells, 15  
  monolayer, 14  
  suspension, 14  
  techniques, 13–16  
  toxicity, in cultured cells, 14–16  
Cell membrane, 16, 78–80  
Cell transformation test, 392  
Cellular methods, in toxicology, 13–22  
Cellular respiration, inhibition, 223  
Central nervous system (CNS), 279–280,  
  379  
CERCLA—*see* Comprehensive  
  Environmental Response,  
  Compensation and Liability Act  
C-Esterase—*see* Esterase  
Checkpoint, 248  
Chelation therapy, 54, 408  
Chemical use classes, 7  
Chemical exposure classes, 11  
Chemical mixtures, 432  
Chlordane, 356, 470  
Chlordecone, 473  
Chlorfenvinphos, 125  
Chlorine, 318  
p-Chlorobenzaldehyde, 134  
1-Chloro-2,4-dinitrobenzene, 144  
Chlorofluorocarbons, 475  
Chloroform, 153, 265, 274, 277,  
Chloroform metabolites, 153, 277  
Chloromethylbenzene, 144  
p-Chlorothiophenol, 141  
Chlorpromazine, 126, 129, 265  
Chlorpyrifos, 59, 122  
Chlorthiazide, 265  
Cholchicine, 265  
Cholestasis, 266  
Cholesterol, 119  
Cholinesterase, 471—*see also*  
  Acetylcholinesterase  
Chromatography, 450–455  
  column, 452  
  gas-liquid, 404, 451  
  high-performance liquid, 404, 454  
  paper, 450  
  thin-layer, 403, 450  
Chromium, 46, 53, 318  
Chromosome aberration tests, 390  
Chromosome translocation, 245, 248  
Chronic toxicity—*see* Toxicity  
Chronic value, 473  
Cigarette smoke, induction by, 199  
Cimetidine, 129  
Cirrhosis, 266  
Clara cells, 318, 323  
Clean Air Act, 412  
Clean Water Act, 412  
Clearance, 106  
Clinical drugs, 4, 7  
Clinical toxicology—*see* Toxicology  
Clofibrate, 139, 191  
Cloning, molecular, 17  
CNS—*see* Central nervous system

- CoA—*see* Coenzyme A  
 Coal dust, 318  
 Cobalt, 4  
 Cocaine, 205  
 Cocarcinogenesis, 528  
 Coenzyme A (CoA), 146  
 Columns, 450, 451  
 Combustion products, 7  
 Compartment, 106, 528  
 Compartmentalization, 204  
 Comprehensive Environmental Response,  
 Compensation and Liability Act  
 (CERCLA), 413  
 Conjugation reactions—*see* Phase II  
 reactions  
 Constitutive active receptor (CAR), 195  
 Consumer Products Safety Act, 354, 413  
 Consumer Products Safety Commission  
 Improvements Act, 413  
 Contact hypersensitivity, 337–338  
 Controlled Substances Act, 413  
 Cooxidation, 132  
 Copper, 4, 165, 166, 492,  
 Cortisol, 300  
 Cosmetics, 71  
 Coumaphos, 126  
 Coumarin, 122, 138  
 Courtroom testimony, 399, 400  
 Covalent binding, 274, 384, 527  
 COX-1, 132  
 COX-2, 132  
 Creatinine, plasma, 274  
 Critical periods, 255  
 Cross resistance, 529  
*Crotalaria spectabilis*, 323  
 Cyanide, 173, 223  
 Cycasin, 159, 160, 265  
 Cycloidiene insecticides, 222  
 Cyclohexamide, 265  
 Cyclooxygenases, 132  
 Cyclophosphamide, 122  
 Cyclosporine A, 123  
 CYP—*see* Cytochrome P450  
 Cysteamine, 129  
 Cytochrome b<sub>5</sub>, 115  
 Cytochrome P450 (CYP), 271, 272, 274,  
 277, 310, 318, 322, 323, 324  
 classification, 117  
 distribution, 116  
 CYP1, 119  
 CYP1A1, 119, 121  
 CYP1A1, induction, 191, 199  
 CYP1A2, 119, 121  
 CYP1A2, induction, 192  
 CYP1B1, 119  
 CYP2, 119, 122  
 CYP2A6, 122  
 CYP2B, regulation, 191, 194  
 CYP2B6, 122  
 CYP2C, 122  
 CYP2C8, 122  
 CYP2C9, 122  
 CYP2C19, 122  
 CYP2D6, 182  
 CYP2E1, 123, 170  
 CYP2E1, regulation, 192, 197  
 CYP3A, regulation, 191, 196, 197  
 CYP3A4, 123, 323  
 CYP19, 310  
 evolution, 117  
 families, 119–123  
 induction, 123  
 multiplicity, 116  
 nomenclature, 117  
 purification, 116  
 reactions, 112, 123–128  
 Cytochrome P450 reductase, 114, 1320,  
 324  
 Cytotoxicity—*see* Toxicity  
 Cysteine conjugate  $\beta$ -lyase—*see*  $\beta$ -Lyase  
 Cytosol, 113
- D**  
 DDE, 174, 204, 348  
 DDT, 57, 58, 137, 198, 204, 222, 307,  
 309, 348, 464, 465, 468  
 DDT dehydrochlorinase, 136  
 Deacetylation, 147  
 Dealkylation (O-, N-, and S-), 112, 124,  
 465  
 Debrisoquine, and polymorphisms, 182  
 Degradation  
 abiotic, 465  
 biotic, 465  
 Dehalogenation, 112, 465  
 Dehydrogenation, 112  
 Delaney Amendment—*see* Food, Drug  
 and Cosmetics Act  
 Demeton, 126  
 Dendrites, 280  
 Dermal  
 irritation tests, 363  
 sensitization tests, 363  
 subchronic toxicity studies, 369  
 DES—*see* Diethylstilbestrol  
 Desulfuration, 112, 127

- Detectors  
  conductivity, 453  
  electron capture, 453  
  flame ionization, 452  
  flame photometric, 453  
  gas-chromatographic, 452
- Detoxication, 529
- Detoxification, 529
- Development, 300
- Developmental toxicity—*see* Toxicity
- Developmental toxicology—*see*  
  Toxicology
- Dexamethasone, 123, 191, 196
- Diabetes, CYP2E1 induction in, 197, 198
- Dialkyl nitrosamines, 265
- Diamine oxidase, 132
- Diazepam, 265
- Diclofenac, 123
- 2,6-Dichlorobenzonitrile, 122
- Dicofol, 465
- Dicoumarol, 224
- Dieldrin, 57, 58, 124, 222, 476
- Dietary administration, in toxicity testing,  
  365
- Diethylmaleate, 144, 185
- Diethylstilbestrol (DES), 256, 299, 306,  
  310, 312, 345
- Diethyltoluamide (DEET), 122
- Diffusion, 80  
  between phases, 486  
  in environment, 485–487  
  passive, 80
- Dihydrotestosterone, 345
- Diffusion, passive, 203
- Digitoxin, 123
- Dimethoate, 175
- Dimethylamine, 128
- Dimethylaniline, 129
- Dimethylbenzanthracene, 121, 265
- Dimethylnitrosamine, 265
- Dimethyl sulfoxide, 126
- 2,4-Dinitrophenol, 224  
  and cataracts, 174
- Dioxin(s), 43, 311, 314
- Diphenylmethylphosphine, 127
- Disease, metabolic effects, 171
- Dispersion, 485
- Distribution, 77–110, 529
- Disulfide reduction, 133
- Disulfiram, 122, 133, 134, 185, 186
- Diurnal rhythms, metabolic effects, 172
- DNA  
  adducts, 240–241, 243–245, 384  
  binding, 270  
  damage, 237–238, 322, 389  
  cDNA libraries, 17  
  recombinant, 16  
  repair, 240–241, 245, 389  
  unscheduled synthesis test, 389
- Dominant lethal test, 392
- Dopamine, 140
- Dosage, 529
- Dose extrapolation, 249, 233–234
- Dose-response, 4, 10, 217–220, 426–427,  
  529
- Dose selection, for chronic studies, 370
- Draize test—*see* Eye irritation test
- Drosophila*, 388
- Drug analysis, 405
- Drug analysis flowchart, 405
- Drugs of abuse, 7, 71, 72, 530
- Drugs, therapeutic, 70, 417, 530
- E**
- EC50, 217
- ED50, 217
- Ecdysone receptor—*see* Receptors
- E. coli*, 386
- Ecotoxicology—*see* Toxicology
- Edema, 318
- EDSTAC—*see* Endocrine Disruptor  
  Screening and Testing Advisory  
  Committee
- Education, 420
- Electrolyte balance, 273
- Electron transport system  
  definition, 530  
  inhibitors, 530
- Electrophilic, 149, 240, 530
- Electrophoresis, capillary, 454
- Elimination of toxicants—*see* Toxicants
- Embryology, mammalian, 252
- Emphysema, 318, 321
- Endoplasmic reticulum, 16, 113, 531
- Endocrine disruptors, 347, 415
- Endocrine Disruptor Screening and  
  Testing Advisory Committee  
  (EDSTAC), 415
- Endocrine system, 299–315
- Endocytosis, 276
- Endosulfan, 126, 473
- Enterohepatic circulation, 208–209, 531
- Environmental fate, 479–499
- Environmental fate models, 479, 497–498
- Environmental Protection Agency, 354,  
  411–416

- Environmental transport, 479–499  
 Epidemiology, 6  
 Epigenetic carcinogen—*see* Carcinogen  
 Epinephrine, 142  
 EPN, 185, 189  
 Epoxidation, 112, 123, 151  
 Epoxide hydrolase, 112, 135, 180  
 1,2-Epoxy-3-(p-nitrophenoxy) propane, 144  
 Erythromycin, 123  
 Esterase(s), 112, 175,  
   A, 135  
   B, 135  
   C, 135  
   and selectivity, 180  
 Ester cleavage, 127  
 Estradiol, 265, 300, 304, 305, 306, 307, 311, 312  
 Estrogen receptor—*see* Receptors  
 Estrogens, 119, 300  
 Estrone, 140  
 Ethanol, 123, 191, 257, 270, 408  
 Ethinyl estradiol, 123  
 Ethionine, 265  
 Ethylene glycol, 407  
 Ethylmorphine, 125  
 Ethylnitrosourea, 345  
 Excretion  
   Biliary, 176  
 Expert witness, 400  
 Exposure, 216  
 Exposure to environmental stress, 508–509  
 Exposure assessment, 425, 507–509, 523, 531  
 Extraction, 447  
   supercritical fluid, 448  
 Extrapolation, animal to human, 354, 362  
 Eye irritation test, 531
- F**  
 Fatty acid(s), 153  
 FDA—*see* Food and Drug Administration  
 Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), 393, 414, 531  
 Fenarimol, 310  
 Fertility, 258, 300  
 Fetal alcohol syndrome, 257, 532  
 Fibrosis, 318, 321  
 Field tests, 394–395  
 FIFRA—*see* Federal Insecticide, Fungicide and Rodenticide Act
- First order kinetics, 82  
 Fish odor syndrome, 128, 183  
 Flavin-containing monooxygenase (FMO), 112, 169, 170, 183, 318, 324  
 Fluoroacetamide, 175  
 FMO—*see* Flavin-containing monooxygenase  
 FOB—*see* Functional observation battery  
 Fonofos, 129  
 Food additives, 7, 64–65, 532  
 Food allergy, 341  
 Food and Drug Administration (FDA), 258, 354, 413  
 Food chains, environmental, 12  
 Food contaminants, 64–65, 532  
 Food, Drug and Cosmetics Act, 413, 532  
 Food Quality Protection Act, 415  
 Formaldehyde, 152  
 Formic acid, 152  
 Forensic toxicology—*see* Toxicology  
 Fumigants, 64  
 Function Observational Battery, 293, 295  
 Fungicides, 63  
 Furans, 314  
*Fusarium solani*, 323  
 Free radicals, 151, 153, 270, 532  
 Functional observation battery (FOB), 379–380  
 Future considerations, environmental, 521  
 Future considerations, human health, 521
- G**  
 GABA—*see*  $\gamma$ -aminobutyric acid  
 Gait, 383  
 Galactosamine, 265  
 Gall bladder, 263  
 Gastrula, 252  
 Gender, metabolic effects, 168  
 Gene  
   amplification, 245  
   expression, 19  
   function, 19  
   regulation, 19  
 Genetic alterations, 237–239, 243  
 Genetic instability, 248  
 Genetic polymorphisms—*see* Polymorphisms  
 Genomic libraries, 17  
 Genotoxic carcinogen—*see* Carcinogen  
 Generally regarded as safe (GRAS), 533  
 Genotoxicity—*see* Toxicity  
 Genotoxicity assays, short assays, 249, 385–393

Gentamycin, 276  
 Germ cells, 345  
 GFAP—*see* Glial Fibrillary Acidic Protein  
 Ginger jake, 288  
 Glial Fibrillary Acidic Protein (GFAP),  
 290, 296  
 Glomerulus, 206  
 Glomerular capsule, 206  
 Glucocorticoid receptor—*see* Receptors  
 Glucocorticoids, 300  
 Glucuronic acid, 209  
 Glucuronidation, developmental effects,  
 167  
 Glucuronide conjugation, 138  
 Glucuronosyl transferase, 138  
 Glucoside conjugation, 139  
 Glutathione, 143, 209  
 Glutathione conjugation, 143, 144, 167,  
 180, 277, 208  
 Glutathione S-transferase—*see*  
 Glutathione conjugation  
 Glycine, 146  
 Glycine conjugation, 167  
 P-Glycoprotein, 209  
 Good laboratory practice, 533  
 GRAS—*see* Generally regarded as safe  
 Growth, 300  
 Growth hormone, 168, 300  
 Gynecomastia, 306, 312, 313

## H

Hair, 205  
 Halogenated hydrocarbons, 249  
 Halothane, 122, 265  
 Hazard assessment, 464, 523  
 Hazard identification, 424  
 Hazard quotient, 432  
 Henry's law, 487–488  
 Hepatic artery, 207, 263  
 Hepatic elimination, 207–210  
 Hepatic portal vein, 263  
 Hepatitis, 267  
 Hepatocytes, 207, 263–272,  
 Hepatotoxicant(s), 3, 4, 263–272  
 Hepatotoxicity—*see* Toxicity  
 Herbicides, 62  
 Hexachlorobenzene, 466, 476  
 Hexachlorobutadiene, 277  
 Hexane, 288  
 Hexobarbital, 174, 183, 186  
 HGPRT test, 387  
 Histamine, 182  
 Homeostasis, 273

Hormesis, 219, 426  
 Hormone, 239, 240, 242  
 clearance, 310  
 synthesis, 310  
 Household chemicals, 417  
 Human genome project, 16  
 Human health risk assessment—*see* Risk  
 Hydrogen fluoride, 318  
 Hydrogen sulfide, 223  
 Hydrolysis, 135, 465, 493  
 Hydroxyacetanilide, 141  
 N-Hydroxy-2-acetylaminofluorene, 139  
 Hydroxylation, 112, 206  
 Hydroxyl radical, 322  
 Hypersensitivity, 335  
 Hypothalamus, 170, 300, 301, 302  
 Hypothalamus-pituitary-gonadal axis, 344  
 Hypothyroidism, 310, 311, 313, 314

## I

Ibuprofen, 123  
 ICH, 258  
 Ifosfamide, 122  
 Imipramine, 122, 129, 138, 265  
 Immune suppression, 330–334  
 Immune system, 327–330  
 Immune system, developing, 341  
 Immunoaffinity purification, 20  
 Immunoassay, 404  
 Immunochemical techniques, 19–21  
 Immunolocalization, 20  
 Immunosuppressive agents, 239  
 Immunotoxicity—*see* Toxicity  
 Imipox, 473, 474  
 Indomethacin, 176, 265  
 Induction, 190, 198, 310, 533  
 Industrial chemicals, 7  
 Industrial toxicology—*see* Toxicology  
 Inhalation toxicity testing, 357  
 Inhibition, 60, 155, 185–188, 224, 310,  
 533  
 Initiation, 241, 534  
 Initiation-promotion model, 241–242  
 Inner cell mass, 252  
 Instrument calibration, 26  
 Insulin, 171  
 Intoxication, 534  
 Involution, 254  
 Ion channels, 222  
 Ionization, 86–87, 490  
 Ionizing radiation, 200  
 Ipomeanol, 323  
 Iproniazid, 265

Iron, 4, 165, 166, 318  
 Irritation, 318, 320  
 Isoniazid, 265  
   and polymorphisms, 182  
 Isotretinoin, 256  
 Isozymes, 534  
 In vitro, 523, 533  
 In vivo, 523, 533

**K**

Kanamycin, 276  
 Kepone, 307, 313  
 Ketaconazole, 310  
 Ketamine, 122  
 Ketone reduction, 134  
 Kidney, 273, 205, 206, *see also* Renal  
   cortex, 273  
   damage, 274  
   medulla, 273  
   papilla, 273  
 Koch's postulates, 511  
 Kupffer cells, 263

**L**

Laboratory Information Management  
   System (LIM), 25  
 LC50, 217, 470, 471, 525, 534  
 LD50, 215, 217, 359–362, 470, 471, 525,  
   534  
 Lead, 38, 41, 47, 51, 275, 285, 287, 290  
 Legislation, 411  
 Lethal synthesis, 534  
 Libido, 300  
 Lidocaine, 123  
 Light, metabolic effects, 200  
 Lindane, 222, 466  
 Lipid, 204  
   effect on metabolism, 164  
 Lipid oxidation, 264  
 Lipid peroxidation, 153, 157, 266, 269,  
   270, 274, 322  
 Lipophilic, 467, 534  
 Lipoproteins, 264, 270  
 Liver  
   and elimination, 206, 207, 209  
   fatty, 264–265  
   function, 263  
   injury, 263–268  
   structure, 263  
   susceptibility to toxicants, 264  
 Local lymph node assay, 337–338  
 LOAEL—*see* Lowest observed adverse  
   effect level

Loop of Henle, 206, 273  
 Lovastatin, 123  
 Lowest observed adverse effect level  
   (LOAEL), 427, 473  
 Lungs, *see* Respiratory system  
 $\beta$ -Lyase, 145, 277, 278  
 Lymphocytes, B, 19–20  
 Lysosomes, 16, 275

**M**

Magnesium, 4  
 Malathion, 181, 473  
 Malformations, developmental, 376–378  
 Mallard duck, 394  
 Manganese, 4, 386  
 Maximum containment level (MCL), 412  
 Maximum containment level goal  
   (MCGL), 412  
 Maximum tolerated dose (MTD), 223,  
   249, 370, 535  
 MCGL—*see* Maximum containment level  
   goal  
 MCL—*see* Maximum containment level  
 Mechanism of action, 535  
 Membranes, 83, 270, 276, 322, 535  
 Mepazine, 265  
 Mephenytoin, 122  
 Mephobarbital, 122  
 Mercaptopurine, 265  
 Mercapturic acids, 143, 166  
 Mercury, 41, 44, 47, 52, 205, 275  
 Mesocosm, 394  
 Mesothelioma, 321, 322,  
 Mestranol, 265  
 Metabolic activation—*see* Activation  
 Metabolism of toxicants—*see* toxicants  
 Metabolism testing, 382  
 Metallothionein, 51, 53, 275  
 Metals, 4, 49–54  
   and nephrotoxicity, 275–276  
   speciation, 492–493  
 Methadone, 122  
 Methandrolone, 265  
 Methanol, 152, 155  
 Methimazole, 265  
 Methiocarb, 126, 129  
 Methiochlor, 126  
 Methionine, 129  
 Methoprene, 308  
 Methoprinic acid, 308  
 Methoxyfluorane, 122, 265  
 N-, O-, S-Methylation, 141, 142  
 Methyl dopa, 265

- Methylenedioxyphenyl synergists, 4  
 Methylenedioxy ring cleavage, 127  
 Methyl mercaptan, 125  
 Methylmercury, 289, 290  
 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 129, 286, 290, 297  
 6-Methylthiopurine, 125  
 Methyltransferase, 141  
 Metyrapone, 185  
 Microbial toxins, 66  
 Microglia, 284, 290  
 Micronucleus test, 391  
 Micronutrients, effects on metabolism, 164  
 Microsomes, 122, 535  
 Midazolam, 123  
 Milk, 204  
 Minimum risk levels (MRL), 427  
 Mirex, 464, 470  
 Mitochondria, 16, 275  
 Mitomycin, 265  
 Mode of action, 535  
 Moisture, effects on metabolism, 200  
 Molecular methods, in toxicology, 13–22  
 Molybdenum hydroxylases, 112  
 Monoamine oxidase, 131, 284, 290  
 Monoclonal, 225–226  
 Monocrotaline, 322  
 Monooxygenase, 535  
 Motility, gut, 300  
 MPTP—*see* 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine  
 MRL—*see* Minimum risk level  
 MTD—*see* Maximum tolerated dose  
 Multidrug-resistance associated protein, 209  
 Multigeneration study, 372–374  
 Mutagenesis, 6, 535  
 Mutagenicity assays, 249, 385–393  
 Mutagenicity study requirements, under FIFRA, 393  
 Mutagens, 121  
 Mutation(s), 237–239, 248–249  
     transition, 248–249  
     translation, 248–249  
 Mycotoxins, 66, 535  
 Myelin, 281, 287, 289–290
- N**
- Naphthalene, 121, 123, 137  
 1-Naphthalene methyl sulfate, 144  
 2-Naphthamine, 138  
 1-Naphthol, 138  
 Naphthylamine, 121, 268  
 Narcosis, 220, 472  
 National Environmental Policy Act, 414  
 National Institute for Occupational Safety and Health (NIOSH), 414, 418  
 NCTB—*see* Neurobehavioral core test battery  
 Necrosis, 266, 321  
 Neomycin, 276  
 Nephron, 206, 273  
 Nephrotoxicity—*see* Toxicity  
 Neurobehavioral core test battery (NCTB), 293–294  
 Neurotoxicity—*see* Toxicity  
 Neurotransmitter  
     receptors, 280, 282–283, 289, 297  
     release, 281–282, 283, 292, 297  
     reuptake, 285, 290  
 Nevirapine, 122  
 Niacin, 165, 166  
 Nickel, 318  
 Nicotine, 122, 129, 130, 141, 173  
 Nifedipine, 123  
 NIOSH—*see* National Institute for Occupational Safety and Health  
 Nitrates, 42  
 p-Nitroanisole, 124  
 Nitroaromatics, 220  
 Nitrobenzene, 134  
 Nitrogen oxides, 37, 318  
 4-Nitrophenol, 140  
 Nitro reduction, 112, 133, 180  
 NOAEL—*see* No observed adverse effect level  
 Nonpoint sources, 480–482  
 Nonsteroidal anti-inflammatory drugs (NSAIDs), 139  
 No observed adverse effect level (NOAEL), 426  
 No observed effect level (NOEL), 10, 472, 525, 536  
 Noradrenaline, 142  
 Norepinephrine, 142  
 Nornicotine, 141  
 Northern blot analysis, 18  
 Nuclear magnetic resonance, 460  
 Nuclear receptors—*see* Receptors  
 Nucleophile, 149  
 Nucleus, 16
- O**
- Occupational Safety and Health Act, 413

- Occupational Safety and Health  
Administration, 354, 413, 418, 536
- OECD, 367
- Oligodendrocyte, 281, 284
- Omeprazole, 122
- Oncogenes, 227, 245–247, 536
- OPIDN—*see* Organophosphate-induced delayed neuropathy
- Organochlorine insecticides, 57–58
- Organophosphate-induced delayed neuropathy (OPIDN), 288
- Organophosphorus insecticides, 58–60, 220, 221, 288, 290–292, 408, 471, 477  
aging, 291–292
- Organogenesis, 371, 374–378
- Organomercurials, 275
- Organ toxicity, 6
- Ornithine, 178
- OSHA—*see* Occupational Safety and Health Administration
- Ovaries, 300, 346
- Oxazepam, 138
- Oxidation, N-, S-, and P-, 112, 126, 127
- Oxidative deamination, 126
- Oxidative phosphorylation, 536
- Oxidative stress, 267, 268, 536
- Oxygen consumption, 300
- Ozone, 37, 318
- P**
- p53, 245, 247–248
- Paclitaxel, 123
- Pantothenic acid, 165, 166
- Papaverine, 265
- Paracelsus, 9, 216
- Paraoxon, 127, 152
- Paraquat, 181
- Parasympathetic nervous system, 280, 291
- Parathion, 58, 59, 127, 152, 155, 465, 466
- Parkinson's Disease, 285, 286, 289, 290
- Partition coefficient, 81, 87–88, 536
- Partitioning, 487  
equilibrium, 487  
lipid-water, 488  
octanol-water, 488  
particle-water, 489
- Passive avoidance, 383
- Passive diffusion—*see* Diffusion
- PBB, 312
- PBPK—*see* Physiologically based pharmacokinetic model
- PCB—*see* Polychlorinated biphenyls
- PCR—*see* Polymerase chain reaction
- Pentachlorophenol, 224
- Peroxisome proliferators, 197
- Peroxisome proliferators-activated receptor- $\alpha$  (PPAR $\alpha$ ), 197
- Persistence, environmental, 464
- Pesticides, 42, 54–64  
classification, 56
- Petroleum, 472
- P-Glycoprotein, 209
- Pharmacokinetics, 78, 537
- Phase I reactions, 111–137, 174, 537
- Phase II reactions, 137–148, 165, 166, 174, 176, 177, 206, 529, 537
- Phenanthrene, 464
- Phenindione, 265
- Phenobarbital, 123, 191, 222, 239, 242
- Phenobarbital-responsive enhancer module (PBREM), 194
- Phenol, 177, 178, 311
- Phenylbutazone, 174, 265
- Phenytoin, 123
- Phorate, 126, 129
- Phorbol 12-myristate 13 acetate (PMA), 239, 242
- 3'-Phosphoadenosine -5'-phosphosulfate (PAPS), 140
- Phosphate conjugation, 147
- Phospholipids, 264, 276
- Phosgene, 156, 277, 318
- Phosphorus, 265
- Photolysis, 465, 494
- Phthalate, 313
- Physiologically based pharmacokinetic model (PBPK), 436
- Phytotoxins, 68
- Piperonyl butoxide, 4, 127, 185, 189
- Pituitary, 301, 302, 170, 171
- PMA—*see* phorbol 12-myristate 13 acetate
- Point sources, 480–482
- Poison—*see also* Toxicant  
definition, 3, 537
- Pollution, 33, 40, 419, 537, 541
- Polychlorinated biphenyls (PCBs), 43, 204, 265, 309, 311, 314, 464, 468, 470, 476
- Polycyclic aromatic hydrocarbons, 71, 73, 121, 243, 249
- Polymerase chain reaction (PCR), 18
- Polymorphisms, 181, 230
- Ploidy, 248
- Polyvinyl chloride, 345

- Poor metabolizers (PM), 122  
 Portals of entry, 4, 537  
 Potentiation—*see* Synergism and potentiation  
 Pregnancy, effects on metabolism, 171  
 Pregnane X receptor (PXR), 196, 197  
 Pregnenolone-16 $\alpha$ -carbonitrile, 191  
 Prevention of toxicity, 411–421  
 Primitive streak, 252  
 Procarcinogen—*see* Carcinogen  
 Procedural manuals, 24  
 Progesterone, 119  
 Progression, 241  
 Proguanil, 122  
 Promazine, 265  
 Promethazine, 129  
 Promotion, 241–243, 537  
 Promoter insertion, 245  
 Propanolol, 138  
 Propiconazole, 310  
 Propofol, 122  
 Prospective assessment, 479–480  
 Prostaglandins, 132, 274  
 Prostaglandin synthase, 132, and cooxidation, 112  
 Protein  
   binding, 97, 270  
   effects on metabolism, 163  
   stabilization, 198  
   synthesis, 17, 264, 266  
 Proto-oncogene, 245  
 Pulmonary toxicity—*see* Toxicity  
 Puromycin, 265  
 Pyrethroid insecticides, 61, 222, 477  
 Pyridoxine, 165, 166  
 Pyrrolizidine alkaloids, 265  
 Physicochemical properties, and diffusion, 85–88
- Q**  
 QA/QC manuals, 24  
 QSAR—*see* Quantitative structure activity relationships  
 Quality assurance, 27  
 Quality control, 27  
 Quantitation, 26  
 Quantitative structure activity relationships (QSAR), 537  
 Quinidine, 123, 187  
 Quinones, 151
- R**  
 Radiation, 237  
 Radioimmunoassay, 21  
 Rainbow trout, 394  
 Rapamycin, 123  
 Ras, 246–247  
 RCRA—*see* Resource Conservation and Recovery Act  
 Reactive oxygen, 149, 151, 267, 322  
 Reactive intermediates (metabolites), 149–161, 269, 538  
 Receptors  
   androgen, 309  
   ecdysone, 307  
   ecological, 505–506, 508  
   estrogen, 303, 306, 308  
   glucocorticoid, 309  
   hormone receptor agonists, 306  
   hormone receptor antagonists, 308  
   nuclear, 302–303  
   retinoic acid, 307  
   retinoid X (RXR), 195, 196, 304, 308, 315  
   steroid, 303  
   thyroid, 303  
 Red book, 367  
 Reduction reactions, 133–135  
 Reference Dose (RfD)—*see* Acceptable Daily Intake  
 Regulation, of toxic chemicals, 353–354, 411  
 Regulatory agencies, 354  
 Renal elimination, 205–207  
 Renal system—*see also* Kidney  
   blood flow, 274  
   cortex, 273  
   function, 273  
   structure, 273  
   susceptibility, 274–275  
   tubules, 273, 274, 275  
 Renin, 274  
 Reproductive physiology  
   female, 346–347  
   male, 343–344  
 Reproductive toxicants—*see* Toxicants  
 Reproductive toxicity—*see* Toxicity  
 Resistance—*see* Adaptation to toxicants  
 Resource Conservation and Recovery Act (RCRA), 414, 538  
 Respiratory system  
   anatomy, 317  
   and elimination, 210  
   cell types, 317  
   function, 317

- Respiratory system (*continued*)  
  lungs, 210  
  susceptibility, 320  
Respiratory toxicity—*see* Toxicity  
Retinoic acid, 122, 304  
Retinoic acid receptor—*see* Receptors  
Retinol, 122  
Retrospective assessment, 479–480  
RfD—*see* Acceptable Daily Intake  
Riboflavin, 165, 166  
Rifampicin, 123, 191, 196  
Risk  
  analysis, 538  
  assessment, 8, 423–438, 521, 538  
  assessment, environmental, 501–517  
  assessment, non-cancer, 427–428  
  characterization, 426–427  
  communication, 8  
  management, 8, 503, 521  
  toxicologic, 538  
RNA  
  hnRNA, 17  
  mRNA, 17  
  processing, 17  
  translation, 17  
Rodenticides, 63  
Rotenone, 223  
Rubella virus, 257  
RXR—*see* Receptors
- S**  
S9, 113, 385  
Safe Drinking Water Act, 412  
Safety factor, 538  
Safety pharmacology studies, 364  
Safrole, 127, 265  
Salmonella assay, 249  
Sample preparation, 447–448  
Sampling,  
  air, 443  
  soil, 444  
  tissue, 445  
  water, 445  
Sarin, 200  
Schwann cells, 284, 287–288  
Segment II study, 371, 374–378  
Selectivity (selective toxicity), 172, 181,  
  524, 538  
Selegiline, 122  
Senescence, effects on metabolism, 167  
Serotonin, 142  
Serum enzymes, 274  
Sexual  
  behavior, 345, 348  
  characteristics, secondary, 300  
  differentiation, 300  
  function, 300  
SHBG, 305, 306  
Signal transduction, 242, 246  
Silica, 318  
Silicosis, 321  
Sinusoids, 207  
Sister chromatid exchange, 390  
SKF 525A, 185, 186  
Skin, 204  
Slope factor, 433  
Soil pollutants, 40  
Solvents, 70, 539  
Somite, 253  
Southern blot analysis, 18  
Spectrometry  
  bimolecular interaction analysis-mass,  
  459  
  induced coupled plasma, 457  
Spectrophotometry  
  infrared, 459  
  ultraviolet/visible, 460  
Spectroscopy  
  atomic absorption, 456  
  mass, 458  
Spermatogenesis, 344  
Sperm quality, 345  
Standard operating procedures, 24  
Starvation, effects on metabolism, 165  
Steroid receptor—*see* Receptors  
Stilbestrol, 176  
Streptomycin, 276  
Stress, effects on metabolism, 200  
Stressors  
  ecological, 502  
  response profile, 510, 512  
  sources, 507, 513  
  susceptibility, 504  
Structure-activity relationships, 6, 354,  
  395  
Styrene 7,8-oxide, 137  
Subchronic toxicity—*see* Toxicity  
Suicide inhibitor, 155  
Suicide substrate, 151, 189  
Sulfanilamide, 265  
Sulfate, 209  
Sulfate conjugation, 139  
Sulfhydryl oxidation, 270  
Sulfotransferase (SULT), 139, 140  
Sulfoxide reduction, 135  
Sulfur dioxide, 318

Sulfur oxides, 36  
 Superoxide anion, 322, 525  
 Superoxide dismutase, 525  
 Surface area, 203  
 Susceptibility, ecosystem, 504  
 Sweat, 204  
 Synergism and potentiation, 189, 381, 539  
 Sympathetic nervous system, 280, 291  
 Synapses, 280, 282, 290  
   postsynaptic, 280, 281  
   presynaptic, 280, 282, 290

## T

Talc, 318  
 Tamoxifen, 123, 129, 308  
 Tannic acid, 265  
 Taxol, 122  
 TCDD, 191, 239, 242, 464, 468, 476  
 Temperature, effects on metabolism, 200  
 Teratogenesis, 6, 251–259, 343, 539  
   multi-generation study, 258  
   single-generation study, 258  
 Teratology, 251, 374–378  
 Testes, 170, 300  
 Testing guidelines, 257–258  
 Testosterone, 169, 300, 305, 310, 311  
 Tetanus toxin, 292  
 Tetrachloroethylene, 265, 318  
 Tetrachloromethane, 153  
 Tetracycline, 181, 265  
 12-O-Tetradecanoyl phorpol-13-acetate,  
   239, 242  
 Tetrafluoroethylene, 278  
 Tetrodotoxin, 173  
 Thalidamide, 256  
 Thelarche, 313  
 Therapy, 539  
 Thermal desorption, 403–404  
 Thiobenzamide, 129  
 Thiophenol, 138  
 Thioridazine, 265  
 Thiourea, 182  
 Threshold, 219, 220  
 Threshold dose, 10, 539  
 Threshold Limit Value(s) (TLV), 44, 418,  
   539  
   ceiling (TLV-C), 418, 539  
   short-term exposure limit (TLV-STEL),  
     418, 539  
   time-weighted average (TLV-TWA),  
     539, 418  
 Thyroid, 300, 303, 304, 310, 311  
 Thyroid hormones, 169, 300

Thyroid receptor—see Receptors  
 Thyroxine, 300, 301  
 TK locus, 387  
 TLV—see Threshold Limit Value  
 TOCP see Tri-*o*-cresylphosphate  
 Tolbutamide, 123  
 Tolerance—see Adaptation to toxicants  
 Tolerance Reassessment Advisory  
   Committee (TRAC), 415  
 Toxic action  
   mechanism of, 5  
   mode of, 5  
 Toxicant(s)  
   chemical effects, on metabolism,  
     184–199  
   comparative effects, on metabolism,  
     172–183  
   definition, 3, 537, 540  
   developmental effects, on metabolism,  
     166  
   distribution, 97–105  
   elimination, 203–211  
   environmental effects, on metabolism,  
     199–200  
   environmental movement, 11  
   fate and effect, 5  
   food chains, 11  
   genetic effects, on metabolism,  
     172–183  
   measurement of, 6  
   metabolism, 111–148  
   nutritional effects, on metabolism,  
     163–166  
   physiological effects, on metabolism,  
     166–172  
   reproductive, 344–348  
   selective, 524  
 Toxicity  
   acute, 215–224, 470, 471, 525  
   acute toxicity tests, 359–363, 525  
   assessment, definition, 353  
   behavioral, 343, 527  
   behavioral toxicity testing, 379–381,  
     383  
   chronic, 472, 528  
   chronic toxicity tests, 370–371, 528  
   cytotoxicity, 529  
   definition, 3  
   developmental, 343, 371–378, 380  
   genotoxicity, 322, 533  
   genotoxicity testing, 385–393  
   hepatotoxicity, 263–272, 274, 277, 533  
   immunotoxicity, 327–338, 533

- Toxicity (*continued*)
- inhalation, 357
  - measurement of, 6
  - nephrotoxicity, 273–278, 536
  - neurotoxicity, 174, 279–297, 536
  - neurotoxicity testing, 378–381
  - prevention 411–421
  - pulmonary, 537
  - reproductive, 343–349
  - reproductive toxicity testing, 371–378
  - respiratory, 317–325
  - selective, 538
  - subchronic, 539
  - subchronic toxicity testing, 363–370
  - testing, 6, 353–397, 533
  - testing requirements, summary, 355
  - testing, routes of administration, 356
  - testing, selection of test species, 366
- Toxicokinetics, 105–109, 382, 540
- Toxicologic pathology, 6
- Toxicology
- analytical, 6, 441–461
  - applied, 6
  - behavioral, 5, 527
  - biochemical, 4, 524
  - clinical, 6, 399–409
  - comparative, 528
  - definition and scope, 3, 540
  - developmental, 251
  - ecotoxicology, 464
  - environmental, 7, 530
  - forensic, 7, 399–409, 532
  - history, 8, 399
  - industrial, 7, 533
  - molecular, 5, 524
  - nutritional, 5
  - occupational, 399
  - regulatory, 7, 399
  - relation to other sciences, 8
  - veterinary, 6
- Toxicology work sheet, forensic, 402
- Toxic Substances Control Act (TSCA), 414, 540
- Toxin(s), 65–69, 67, 540
- TPA—*see* 12-O-Tetradecanoyl phorpol-13-acetate
- TRAC—*see* Tolerance Reassessment Advisory Committee
- Transcription, 16
- Transmethylation, 311
- Transport, 205, 540
- carrier-mediated, 84–85
  - Fickian, 485
  - in environment, 483–487
  - mechanisms, 80
- Triazolam, 123
- Tributyl tin, 473
- Trichloroethylene, 265
- Trichloromethanol, 277
- Trichloromethyl radical, 269
- Trichloromethylperoxy radical, 269
- Tri-*o*-cresylphosphate (TOCP), 288
- Triglyceride cycle, 265
- Trimethylacetophenone, 126
- Trimethylamine, 128, 129
- Trimethylaminourea, 128, 183
- Tryptamine, 142
- TSCA—*see* Toxic Substances Control Act
- Tumors
- benign, 227–228
  - malignant, 227–228
  - promoters, 239–243
  - suppressor genes, 227, 247–248
- Type I ligands, 114
- Type II ligands, 114
- Type III ligands, 114
- U**
- Ultimate carcinogen—*see* Carcinogen
- Uncertainty, 423
- Uncertainty factor—*see* Safety factor
- Uranium, 276
- Ureter, 273
- Urethane, 265
- Urethra, 273
- Uridine diphospho glucuronic acid (UDPGA), 138
- Uridine glucuronosyl transferase (UGT), 139
- Urinary bladder, 273
- Urine, 206, 399
- Uterine effects, 348
- UVR, 237, 245, 248
- V**
- Valproic acid, 122, 139
- Venom, 68, 540
- Vinclozalin, 309
- Vinyl chloride, 3, 152, 155, 189, 265, 268
- Vitamin D, 274
- Volatile organic compounds, 38, 43
- Volume of distribution, 103
- W**
- Wallerian degeneration, 288
- Warfarin, 123
- Waste reduction, 420

Water pollution, 419, 541  
Weight-of-evidence, 433  
Western blot analysis, 21  
Worker Protection Standard for  
Agricultural Pesticides, 415  
Wound healing, 300

**X**

Xenobiotic, 541

Xenobiotic-metabolizing enzymes, 4  
Xenobiotic-responsive element (XRE),  
193  
Xenobiotic-responsive enhancer module  
(XREM), 196

**Z**

Zinc, 4  
Zoxazolamine, 198, 265